Bergen, 24 April 2007: New NorDiag product: - Makes Chlamydia diagnostics more efficient

NorDiag launches a new sample preparation product for gene based analysis of sexually transmitted diseases.

The new system facilitates a 100% increase in speed of processing samples. Hence, the laboratories can handle tests more efficiently and at significantly reduced cost. NorDiag expects that the new product will contribute substantially to the company`s business volume internationally.

Chlamydia is among the most common sexually transmitted diseases. The infection is relatively easy curable with antibiotics. However, as up to 75% of the women and 50% of the men infected are free of symptoms, routine examination (screening) and early diagnosis are key elements to reduce the high prevalence of this infection. NorDiag`s system isolates bacterial DNA from urine tests, which contributes to an accurate diagnosis.

NorDiag currently sells the product in the Nordic Countries, and 14 hospitals use NorDiag`s system as part of the daily routine. Conversion to the new system will lead to faster processing and significant cost savings.

- If health authorities evaluate screening programmes against Chlamydia, the new system can contribute to considerable cost savings in such programmes, says CEO Mårten Wigstøl. He adds that sexually transmitted diseases constitute a target area for NorDiag, and he expects that the new product will increase the company`s business volume in 2007. - The Nordic Countries account for approximately 4% of the market for sexually transmitted diseases. A replication of NorDiag`s current Nordic market share on the worldwide market would mean considerable revenues from a total market of approximately 25 million tests.

Contact person: CEO Mårten Wigstøl, phone + 47 91165775

About NorDiag ASA
NorDiag is a biotechnology company with focus on genetic diagnostics in the fields of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. The company has other applications for diagnosis of cancer under development, among others a screening product for colorectal cancer. In addition the company has a product for automated sample preparation of sexually transmitted diseases, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.